Search Within

Heather Jolie Landau

  1. "Roni Tamari"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (5)
Groups
  1. Bone Marrow Transplant (14)
  2. CTCR Scholars (14)
  3. Center for Hematologic Malignancies (14)
  4. Department of Medicine (14)
  5. Hematologic Malignancies, Division of (14)
  6. MSK Grad Students (14)

More Groups

People
  1. Roni Tamari (14)
  2. Sergio Giralt (14)
  3. David Chung (9)
  4. Parastoo Dahi (9)
  5. Miguel-Angel Perales (7)
  6. Sean Devlin (7)

More People

Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (1)
  5. 2018 (3)
  6. 2017 (3)

More Years

Publications
  1. Biology of Blood and Marrow Transplantation (5)
  2. Blood (5)
  3. Bone Marrow Transplantation (1)
  4. British Journal of Haematology (1)
  5. Science Translational Medicine (1)
  6. Transplantation and Cellular Therapy (1)
Publishers
  1. Elsevier Inc. (6)
  2. American Society of Hematology (5)
  3. American Association for the Advancement of Science (1)
  4. John Wiley & Sons (1)
  5. Nature Publishing Group (1)

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation
    Journal Article

    Elias, S.; Brown, S.; Devlin, S. M.; Barker, J. N.; Cho, C.; Chung, D. J.; Dahi, P. B.; Giralt, S.; Gyurkocza, B.; Jakubowski, A. A.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse
    Journal Article

    DeWolf, S.; Elhanati, Y.; Nichols, K.; Waters, N. R.; Nguyen, C. L.; Slingerland, J. B.; Rodriguez, N.; Lyudovyk, O.; Giardina, P. A.; Kousa, A. I.; more...
    Science Translational Medicine (2023)

    Fulltext@MSK | Save
  • Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant
    Journal Article

    Sola, M.; Bhatt, V.; Palazzo, M.; Cavalier, K. E.; Devlin, S. M.; Maloy, M.; Barker, J. N.; Castro-Malaspina, H.; Chung, D.; Dahi, P. B.; more...
    Bone Marrow Transplantation (2022)

    Fulltext@MSK | Save
  • Cellular therapy during COVID-19: Lessons learned and preparing for subsequent waves
    Journal Article

    Nawas, M. T.; Shah, G. L.; Feldman, D. R.; Ruiz, J. D.; Robilotti, E. V.; Aslam, A. A.; Dundas, M.; Kamboj, M.; Barker, J. N.; Cho, C.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • TCR repertoires in graft-versus-host-disease (GVHD)-target tissues reveals tissue specificity of the alloimmune response
    Meeting Abstract

    DeWolf, S.; Nichols, K.; Nguyen, C. L.; Giardina, P. A.; Slingerland, J. B.; Elias, H.; Kappangantula, R.; Baez, P.; Murali, R.; Hayashi, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase 1/2 trial of carfilzomib plus high-dose melphalan preparative regimen for salvage autologous hematopoietic cell transplantation followed by maintenance carfilzomib in patients with relapsed/refractory multiple myeloma
    Journal Article

    Costa, L. J.; Landau, H. J.; Chhabra, S.; Hari, P.; Innis-Shelton, R.; Godby, K. N.; Hamadani, M.; Tamari, R.; Anderton, K.; Dixon, P.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Feasibility and toxicity of Pharmacokinetic (PK)-directed dosing of Evomela® (propylene glycol free melphalan, PGF-MEL) for multiple myeloma (MM) and AL amyloidosis (AL) patients undergoing autologous hematopoietic stem cell transplant (AHCT)
    Meeting Abstract

    Shah, G. L.; Lin, A.; Schofield, R.; Sarubbi, C.; Preston, E. V.; Devlin, S. M.; Bhatt, V.; Harnicar, S.; Hoover, E.; Chung, D. J.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Pharmacokinetics and toxicities after Evomela® (propylene glycol free melphalan) with hematopoietic stem cell transplant (HCT) for multiple myeloma (MM), AL amyloidosis (AL), lymphoma, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS)
    Meeting Abstract

    Shah, G. L.; Landau, H.; Sarubbi, C.; Schofield, R.; Lin, A.; Bhatt, V.; Harnicar, S.; Devlin, S. M.; Castro-Malaspina, H.; Chung, D. J.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • A phase 1/2 trial of carfilzomib + high dose melphalan conditioning for auto-HCT followed by carfilzomib maintenance for patients with relapsed multiple myeloma
    Meeting Abstract

    Costa, L. J.; Landau, H.; Chhabra, S.; Hari, P.; Innis-Shelton, R.; Saad, A.; Salzman, D.; Hamadani, M.; Tamari, R.; Williams, L.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Feasibility, tolerability, and patient-reported outcomes with pharmacokinetic (PK)-directed dosing of Evomela (propylene glycol free melphalan) for multiple myeloma and AL amyloidosis patients undergoing autologous hematopoietic stem cell transplant (AHCT)
    Meeting Abstract

    Shah, G. L.; Lin, A.; Schofield, R.; Sarubbi, C.; Preston, E. V.; Devlin, S. M.; Bhatt, V.; Harnicar, S. J.; Hoover, E.; Chung, D. J.; more...
    Blood (2017)

    Fulltext@MSK | Save